

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Moxifloxacin Liquid Formulation

Version 3.0      Revision Date: 17.06.2025      SDS Number: 1732581-00018      Date of last issue: 14.04.2025  
Date of first issue: 05.06.2017

---

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

#### 1.1 Product identifier

Trade name : Moxifloxacin Liquid Formulation

#### 1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Substance/Mixture : Pharmaceutical

Recommended restrictions on use : Not applicable

#### 1.3 Details of the supplier of the safety data sheet

Company : MSD  
Kilsheelan  
Clonmel Tipperary, IE

Telephone : 353-51-601000

E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

#### 1.4 Emergency telephone number

+1-908-423-6000

---

### SECTION 2: Hazards identification

#### 2.1 Classification of the substance or mixture

##### Classification (REGULATION (EC) No 1272/2008)

Not a hazardous substance or mixture.

#### 2.2 Label elements

##### Labelling (REGULATION (EC) No 1272/2008)

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required.

EUH210      Safety data sheet available on request.

#### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Moxifloxacin Liquid Formulation

Version  
3.0

Revision Date:  
17.06.2025

SDS Number:  
1732581-00018

Date of last issue: 14.04.2025  
Date of first issue: 05.06.2017

---

**Ecological information:** The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

**Toxicological information:** The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

---

## SECTION 3: Composition/information on ingredients

### 3.2 Mixtures

#### Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Moxifloxacin HCL	186826-86-8	Acute Tox. 4; H302 Eye Irrit. 2; H319 Repr. 2; H361d STOT RE 2; H373 (Liver)	>= 0,1 - < 1

For explanation of abbreviations see section 16.

---

## SECTION 4: First aid measures

### 4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.  
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.

In case of eye contact : Flush eyes with water as a precaution.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Moxifloxacin Liquid Formulation

Version  
3.0

Revision Date:  
17.06.2025

SDS Number:  
1732581-00018

Date of last issue: 14.04.2025  
Date of first issue: 05.06.2017

---

Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention.  
Rinse mouth thoroughly with water.

### 4.2 Most important symptoms and effects, both acute and delayed

None known.

### 4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

---

## SECTION 5: Firefighting measures

### 5.1 Extinguishing media

Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical

Unsuitable extinguishing media : None known.

### 5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : No hazardous combustion products are known

### 5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

---

## SECTION 6: Accidental release measures

### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Moxifloxacin Liquid Formulation

Version  
3.0

Revision Date:  
17.06.2025

SDS Number:  
1732581-00018

Date of last issue: 14.04.2025  
Date of first issue: 05.06.2017

---

### 6.2 Environmental precautions

Environmental precautions

- : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Prevent spreading over a wide area (e.g. by containment or oil barriers).  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up

- : Soak up with inert absorbent material.  
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.  
Clean up remaining materials from spill with suitable absorbent.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

---

## SECTION 7: Handling and storage

### 7.1 Precautions for safe handling

Technical measures

- : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation

- : Use only with adequate ventilation.

Advice on safe handling

- : Avoid inhalation of vapour or mist.  
Do not swallow.  
Avoid contact with eyes.  
Avoid prolonged or repeated contact with skin.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures

- : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Moxifloxacin Liquid Formulation

Version  
3.0

Revision Date:  
17.06.2025

SDS Number:  
1732581-00018

Date of last issue: 14.04.2025  
Date of first issue: 05.06.2017

---

### 7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers : Keep in properly labelled containers. Store in accordance with the particular national regulations.

Advice on common storage : Do not store with the following product types:  
Strong oxidizing agents  
Gases

### 7.3 Specific end use(s)

Specific use(s) : No data available

---

## SECTION 8: Exposure controls/personal protection

### 8.1 Control parameters

#### Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Moxifloxacin HCL	186826-86-8	TWA	1000 µg/m3 (OEB 1)	Internal

### 8.2 Exposure controls

#### Engineering measures

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Laboratory operations do not require special containment.

#### Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection  
Material : Chemical-resistant gloves

Skin and body protection : Work uniform or laboratory coat.

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.  
Equipment should conform to NS EN 143

Filter type : Particulates type (P)

---

## SECTION 9: Physical and chemical properties

### 9.1 Information on basic physical and chemical properties

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Moxifloxacin Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
3.0	17.06.2025	1732581-00018	Date of first issue: 05.06.2017

Physical state	:	liquid
Colour	:	yellow
Odour	:	odourless
Odour Threshold	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Flash point	:	No data available
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
pH	:	4,1 - 4,6
Viscosity	:	No data available
Viscosity, kinematic	:	No data available
Solubility(ies)	:	No data available
Water solubility	:	slightly soluble
Partition coefficient: n-octanol/water	:	No data available
Vapour pressure	:	No data available
Relative density	:	No data available
Density	:	1,0044 g/cm <sup>3</sup> (20 °C)
Relative vapour density	:	No data available
Particle characteristics	:	No data available
Particle size	:	No data available

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Moxifloxacin Liquid Formulation

Version 3.0	Revision Date: 17.06.2025	SDS Number: 1732581-00018	Date of last issue: 14.04.2025 Date of first issue: 05.06.2017
----------------	------------------------------	------------------------------	---

---

### 9.2 Other information

Explosives	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Evaporation rate	:	No data available
Molecular weight	:	No data available

---

## SECTION 10: Stability and reactivity

### 10.1 Reactivity

Not classified as a reactivity hazard.

### 10.2 Chemical stability

Stable under normal conditions.

### 10.3 Possibility of hazardous reactions

Hazardous reactions	:	Can react with strong oxidizing agents.
---------------------	---	---

### 10.4 Conditions to avoid

Conditions to avoid	:	None known.
---------------------	---	-------------

### 10.5 Incompatible materials

Materials to avoid	:	Oxidizing agents
--------------------	---	------------------

### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

---

## SECTION 11: Toxicological information

### 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of exposure	:	Inhalation Skin contact Ingestion Eye contact
--	---	--

#### Acute toxicity

Not classified based on available information.

#### Components:

#### Moxifloxacin HCL:

Acute oral toxicity	:	LD50 (Rat): 1.320 mg/kg LD50 (Mouse): > 435 mg/kg LD50 (Monkey): 1.500 mg/kg
---------------------	---	--

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Moxifloxacin Liquid Formulation

Version  
3.0

Revision Date:  
17.06.2025

SDS Number:  
1732581-00018

Date of last issue: 14.04.2025  
Date of first issue: 05.06.2017

---

II

### Skin corrosion/irritation

Not classified based on available information.

#### Components:

##### Moxifloxacin HCL:

Species	:	Rabbit
Result	:	No skin irritation

### Serious eye damage/eye irritation

Not classified based on available information.

#### Components:

##### Moxifloxacin HCL:

Species	:	Rabbit
Result	:	Moderate eye irritation

### Respiratory or skin sensitisation

#### Skin sensitisation

Not classified based on available information.

#### Respiratory sensitisation

Not classified based on available information.

#### Germ cell mutagenicity

Not classified based on available information.

#### Components:

##### Moxifloxacin HCL:

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: positive
		Test Type: Chromosome aberration test in vitro Result: negative
		Test Type: In vitro mammalian cell gene mutation test Result: negative
		Test Type: in vitro micronucleus test Result: negative
Genotoxicity in vivo	:	Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Application Route: Oral Result: negative

### Carcinogenicity

Not classified based on available information.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Moxifloxacin Liquid Formulation

Version  
3.0

Revision Date:  
17.06.2025

SDS Number:  
1732581-00018

Date of last issue: 14.04.2025  
Date of first issue: 05.06.2017

### Reproductive toxicity

Not classified based on available information.

#### Components:

##### **Moxifloxacin HCL:**

Effects on fertility	: Test Type: Fertility/early embryonic development Species: Rat Application Route: Oral Fertility: LOAEL: 500 mg/kg body weight Result: Effects on fertility
Effects on foetal development	: Test Type: Embryo-foetal development Species: Monkey Application Route: Oral Developmental Toxicity: NOAEL: 10 mg/kg body weight Result: negative
	Test Type: Embryo-foetal development Species: Rabbit Application Route: Intravenous injection Developmental Toxicity: LOAEL: 20 mg/kg body weight Symptoms: Skeletal malformations
Reproductive toxicity - Assessment	: Some evidence of adverse effects on development, based on animal experiments.

### STOT - single exposure

Not classified based on available information.

### STOT - repeated exposure

Not classified based on available information.

#### Components:

##### **Moxifloxacin HCL:**

Target Organs Assessment	: Liver : May cause damage to organs through prolonged or repeated exposure.
--------------------------	---

### Repeated dose toxicity

#### Components:

##### **Moxifloxacin HCL:**

Species	: Rat
LOAEL	: 100 mg/kg
Application Route	: Oral
Exposure time	: 4 Weeks

Species	: Rat
NOAEL	: 100 mg/kg
Application Route	: Oral

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Moxifloxacin Liquid Formulation

Version 3.0      Revision Date: 17.06.2025      SDS Number: 1732581-00018      Date of last issue: 14.04.2025  
Date of first issue: 05.06.2017

---

Exposure time	:	13 Weeks
Target Organs	:	Liver
Symptoms	:	Liver disorders
Species	:	Rat
NOAEL	:	20 mg/kg
Application Route	:	Oral
Exposure time	:	6 Months
Target Organs	:	Liver
Symptoms	:	Liver disorders
Species	:	Monkey
NOAEL	:	50 mg/kg
Application Route	:	Oral
Exposure time	:	4 Weeks
Symptoms	:	No adverse effects
Species	:	Monkey
NOAEL	:	15 mg/kg
Application Route	:	Oral
Exposure time	:	13 Weeks
Target Organs	:	Gastrointestinal tract
Symptoms	:	Vomiting
Species	:	Monkey
Application Route	:	Oral
Exposure time	:	26 Weeks
Target Organs	:	Liver
Symptoms	:	Liver disorders

### Aspiration toxicity

Not classified based on available information.

## 11.2 Information on other hazards

### Endocrine disrupting properties

Not classified based on available information.

### Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

### Experience with human exposure

### Components:

#### Moxifloxacin HCL:

Ingestion	: Symptoms: Nausea, Abdominal pain, Headache, Dizziness, central nervous system effects, joint pain
-----------	---

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Moxifloxacin Liquid Formulation

Version  
3.0

Revision Date:  
17.06.2025

SDS Number:  
1732581-00018

Date of last issue: 14.04.2025  
Date of first issue: 05.06.2017

---

## SECTION 12: Ecological information

### 12.1 Toxicity

No data available

### 12.2 Persistence and degradability

No data available

### 12.3 Bioaccumulative potential

No data available

### 12.4 Mobility in soil

No data available

### 12.5 Results of PBT and vPvB assessment

#### Product:

Assessment

: This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

### 12.6 Endocrine disrupting properties

#### Product:

Assessment

: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

### 12.7 Other adverse effects

No data available

---

## SECTION 13: Disposal considerations

### 13.1 Waste treatment methods

Product

: Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.

Contaminated packaging

: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Moxifloxacin Liquid Formulation

Version  
3.0

Revision Date:  
17.06.2025

SDS Number:  
1732581-00018

Date of last issue: 14.04.2025  
Date of first issue: 05.06.2017

---

### SECTION 14: Transport information

#### 14.1 UN number or ID number

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
IATA	:	Not regulated as a dangerous good

#### 14.2 UN proper shipping name

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
IATA	:	Not regulated as a dangerous good

#### 14.3 Transport hazard class(es)

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
IATA	:	Not regulated as a dangerous good

#### 14.4 Packing group

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
IATA (Cargo)	:	Not regulated as a dangerous good
IATA (Passenger)	:	Not regulated as a dangerous good

#### 14.5 Environmental hazards

Not regulated as a dangerous good

#### 14.6 Special precautions for user

Not applicable

#### 14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

## SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Moxifloxacin Liquid Formulation**

Version Revision Date: SDS Number: Date of last issue: 14.04.2025  
3.0 17.06.2025 1732581-00018 Date of first issue: 05.06.2017

## **SECTION 15: Regulatory information**

## 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII)	:	Not applicable
REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).	:	Not applicable
REACH - List of substances subject to authorisation (Annex XIV)	:	Not applicable
Regulation (EU) No 2024/590 on substances that deplete the ozone layer	:	Not applicable
Regulation (EU) 2019/1021 on persistent organic pollutants (recast)	:	Not applicable
Regulation (EU) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals	:	Not applicable
Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.		Not applicable

**The components of this product are reported in the following inventories:**

AICS : not determined  
DSL : not determined  
IECSC : not determined

## 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out

---

## SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

## Full text of H-Statements

H302 : Harmful if swallowed.  
H319 : Causes serious eye irritation.  
H361d : Suspected of damaging the unborn child.  
H373 : May cause damage to organs through prolonged or repeated exposure.

### Full text of other abbreviations

Full text of other abbreviations	
Acute Tox.	: Acute toxicity
Eye Irrit.	: Eye irritation
Repr.	: Reproductive toxicity
STOT RE	: Specific target organ toxicity - repeated exposure

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Moxifloxacin Liquid Formulation

Version  
3.0

Revision Date:  
17.06.2025

SDS Number:  
1732581-00018

Date of last issue: 14.04.2025  
Date of first issue: 05.06.2017

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

### Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NO / EN

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Moxifloxacin Liquid Formulation

Version  
3.0

Revision Date:  
17.06.2025

SDS Number:  
1732581-00018

Date of last issue: 14.04.2025  
Date of first issue: 05.06.2017

---